Stock Ratings / Health Care / LGVN / dividends

BGMS (40) SCNX (42) GELS (59) SKYE (36) ⌘ Pro Terminal →

Longeveron Inc. (Class A) (LGVN) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Is LGVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Longeveron Inc. (Class A) (NASDAQ: LGVN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.75 (-1.68% 1D, market cap $5.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LGVN ranks #903 in composite RQD confidence.

Q: How does LGVN compare to BGMS and SCNX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LGVN carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 67.0%, and ROIC of -35.0%. By comparison, BGMS (Bio Green Med Solution Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and SCNX (Scienture Holdings Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, LGVN leads on earnings multiple (N/A) while LGVN leads on capital efficiency (-35.0% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for LGVN?

Per LGVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001721484), Longeveron Inc. (Class A) generated $1.2M in revenue (-49.9% YoY), -$22.7M in net income, and -$18.9M in free cash flow against $10.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is LGVN trading relative to its 50-day, 200-day, and 52-week technical levels?

LGVN last traded at $1.75 (-1.68% on volume of 64,778 shares), positioning the stock -55.13% below its 50-day simple moving average ($3.90) and -73.64% below its 200-day simple moving average ($6.64). Across its 52-week range of $1.31 to $12.30, LGVN sits at the 4.0% percentile with a 14-day RSI of 31.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.53 to $1.97).

Q: Does LGVN pay a dividend and is it safe?

Longeveron Inc. (Class A) (LGVN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$1.75 -1.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.74

Longeveron Inc. (Class A) (LGVN) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $5.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.74 (-0.49%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LGVN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY LGVN SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 31.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.48-44% Next Q

Q2 (-2Q)

Grade E$1.39+15.1% Next Q

Q3 (-1Q)

Grade E$1.60+9.4% Next Q

Current

Grade E$1.75-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LGVN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LGVN currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.90) and Max Pain ($1.84) forces dealer call-delta covering toward $12.92.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LGVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LGVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LGVN)

✓Walkthrough of LGVN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LGVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.41%📐 HORIZONTAL RANGE

2026-10-30O $1.78H $1.80L $1.58C $1.75VOL 80.7K

RES: $8.83SUP: $0.87SMA50: $3.90SMA200: $6.64

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LGVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LGVN Butterfly Map → + Track LGVN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -49.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LGVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LGVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LGVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LGVN)

Health Care Rank #903 of 1016 ⚔️ BGMS vs LGVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LGVN vs. BGMS, SCNX, GELS, SKYE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Longeveron Inc. (Class A) (LGVN) ranks #903 by composite RQD confidence (32/100, grade E) and #936 by equity capitalization ($5.6M). Within this direct 5-issuer industry benchmark cohort, LGVN leads on earnings valuation at N/A trailing P/E, while LGVN leads on capital efficiency and profitability with -35.0% ROIC and 67.0% gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with LGVN at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LGVN ACTIVE Longeveron Inc. (Class A)	E	32/100	—	67.0%	-35.0%	-1.68%	$5.6M	Benchmark Subject
BGMS Bio Green Med Solution Inc.	D-	40/100	—	—	-35.0%	-9.79%	$5.5M	/bgms-vs-lgvn →
SCNX Scienture Holdings Inc.	D-	42/100	—	76.8%	-35.0%	+2.65%	$5.7M	/scnx-vs-lgvn →
GELS Gelteq Limited	C-	59/100	—	—	—	+5.11%	$5.4M	/gels-vs-lgvn →
SKYE Skye Bioscience Inc.	D-	36/100	—	—	-35.0%	-13.82%	$5.8M	/skye-vs-lgvn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001721484

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Longeveron Inc. (Class A) (LGVN) reported GAAP revenue of $1.2M (-49.9% vs. FY2024 revenue of $2.4M , and +69.1% cumulative change since FY2023) , GAAP net income of -$22.7M, operating cash flow of -$18.6M, and free cash flow of -$18.9M (-30.1% YoY). On the balance sheet, LGVN closed FY2025 with $10.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.2M	-$22.7M	-$18.6M	-$18.9M	$10.3M	—
FY2024 (FY)	2024-12-31	$2.4M	-$16.0M	-$13.9M	-$14.5M	$25.6M	—
FY2023 (FY)	2023-12-31	$709.0K	-$21.4M	-$19.0M	-$19.0M	—	—

3. LGVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LGVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Longeveron Inc. (Class A) (NASDAQ: LGVN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.75 (-1.68% 1D, market cap $5.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LGVN ranks #903 in composite RQD confidence.

How does LGVN compare to BGMS and SCNX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LGVN carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 67.0%, and ROIC of -35.0%. By comparison, BGMS (Bio Green Med Solution Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and SCNX (Scienture Holdings Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, LGVN leads on earnings multiple (N/A) while LGVN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LGVN?

Per LGVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001721484), Longeveron Inc. (Class A) generated $1.2M in revenue (-49.9% YoY), -$22.7M in net income, and -$18.9M in free cash flow against $10.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LGVN trading relative to its 50-day, 200-day, and 52-week technical levels?

LGVN last traded at $1.75 (-1.68% on volume of 64,778 shares), positioning the stock -55.13% below its 50-day simple moving average ($3.90) and -73.64% below its 200-day simple moving average ($6.64). Across its 52-week range of $1.31 to $12.30, LGVN sits at the 4.0% percentile with a 14-day RSI of 31.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.53 to $1.97).

LGVN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does LGVN pay a dividend and is it safe?

Longeveron Inc. (Class A) (LGVN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: LGVN RQD Cockpit LGVN 12M Forecast LGVN Earnings & Move LGVN Dividends & DRIP LGVN Insiders & 13F LGVN Whale Options LGVN Profit Sankey LGVN News & Why